Adaptive designs in clinical trials: why use them, and how to run and report them
Philip Pallmann(University of Liverpool), Thomas Jaki(MRC Biostatistics Unit)
Cited by 826
Related Papers
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
|The Lancet|2020|3.7k
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Respiratory Medicine|2026|1